Untitled

At F Plus Healthcare, we design and manufacture pharmaceutical machinery , from high-shear granulators to rigid barrier isolators for pharmaceutical companies across Europe, Asia, and the Middle East. Over the past two years, we have seen a consistent shift in what procurement and engineering teams ask for. The questions have changed from 'what does a granulation machine produce?' to 'how does this machine prove what it produced?'

This article is a systematic attempt to connect the dots between macro-level regulatory trends and the equipment decisions that manufacturing teams face today, with a specific focus on granulation and containment systems.

Regulatory frameworks covered in this article:

•       ICH Q13 : Continuous Manufacturing

•       OEB Framework: Occupational Exposure Bands

•       Equipment as a data-generating compliance asset

•       EU GMP Annex 11 and AI-specific requirements

•       FRAME: FDA's real-time manufacturing framework

•       Global GMP harmonisation

ICH Q13 and What It Demands of Your Granulation Line

ICH Q13 is not a trend. It is a guideline formally adopted in 2023 that has now had over two years of real-world implementation across regulated markets.

Its global adoption has triggered a structural shift on the production floor. Pharma manufacturers are moving away from discrete batch processing and toward continuous granulation workflows, a transition that demands more than new hardware. ICH Q13 requires manufacturers to demonstrate full material traceability throughout the manufacturing process, meaning that every gram of input material must be tracked, logged, and attributable to a specific output.

For equipment procurement teams, this changes the selection criteria. The primary question is no longer about achieving a target particle size distribution with the right granulation machine. It is about documentation, control, and auditability over every stage of the process. ICH Q13 also requires compatibility with Process Analytical Technology (PAT) tools, which enable in-line measurement and real-time quality assessment during production.

In practical terms, a granulation line purchased today must demonstrate:

•       RTD (Residence Time Distribution) characterisation for continuous processes

•       Validated PAT integration with documented measurement methods

•       Control strategies that can detect and respond to process disturbances in real time

•       Transparent AI or model-based decision logic that can withstand regulatory scrutiny

•       Attention to process containment to minimise cross-contamination risk

How the OEB Framework Is Reshaping Containment Equipment Selection

The Occupational Exposure Band (OEB) system has been an industry standard for over two decades. However, the regulatory environment around it has tightened considerably.

Two developments are driving this:

First, the revised EU GMP Annex 1 has redefined contamination control. It is no longer limited to sterility assurance. It now demands a holistic contamination control strategyContamination Control Strategy (CCS) that covers the entire manufacturing environment. Second, the high-potency active pharmaceutical ingredient (HPAPI) market is growing at approximately 9% CAGR, meaning that a larger proportion of compounds being manufactured today require the highest levels of containment.

For manufacturing teams processing HPAPIs, a properly specified containment system is not optional. Closed System Transfer Devices (CSTDs) now complement primary containment as a standard expectation, not an upgrade.

Granulation, which was historically a relatively open process, now increasingly requires fully integrated closed-loop architecture. Rigid barrier isolators fully enclosed granulation systems designed for blending, dispensing, and sampling operations provide operator protection through HEPA/ULPA air filtration, negative pressure environments, and integrated decontamination features.

In 2026, documentation requirements for containment systems extend well beyond the traditional OQ/PQ validation package. Regulators across Europe, the US, and Asia-Pacific now expect:

•       Validated containment performance data, typically expressed as Surrogate Powder Testing using lactose or naproxen

•       Documented CIP/WIP validation cycles

The pharmaceutical industry is rapidly evolving, driven by the need for higher efficiency, improved product quality, and strict regulatory compliance. One of the most transformative innovations in this space is the integrated granulation line. By combining multiple processing steps into a single, streamlined system, manufacturers can achieve consistent results while reducing operational complexity.

An integrated granulation line brings together mixing, granulating, drying, and milling into a unified process. Traditionally, these steps were handled separately, requiring manual intervention and increasing the risk of contamination or variability. With automation at its core, this modern approach ensures precise control over critical parameters such as temperature, moisture, and particle size distribution.

At the heart of this system lies the granulation machine, which plays a crucial role in converting fine powders into uniform granules. These granules are essential for producing tablets and capsules with consistent dosage and optimal dissolution properties. By integrating the granulation machine within a continuous line, manufacturers can minimize material handling and significantly reduce production time.

Another key advantage is scalability. Integrated systems can be easily adjusted to meet changing production demands, making them ideal for both large-scale manufacturing and smaller, specialized batches. Additionally, real-time monitoring and data analytics enable better decision-making, ensuring compliance with Good Manufacturing Practices (GMP).

The use of a granulation machine within an integrated setup also enhances energy efficiency and reduces waste. Continuous processing eliminates downtime between steps, leading to higher throughput and lower operational costs. Furthermore, the compact design of these systems optimizes facility space, a critical factor in modern pharmaceutical plants.